SCHEMBL1099642

SCHEMBL1099642

O=S(=O)(c1ccccn1)N(Cc1ccc(F)c(F)c1)c1cc2ccccc2s1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.37
CXCR3 P49682 3/20 0.36
OXTR P30559 2/20 0.36
GLO1 Q04760 1/20 0.34
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NFE2L2 Q16236 1/20 0.33
EP300 Q09472 1/20 0.33
KCNA5 P22460 1/20 0.33
SLC40A1 Q9NP59 1/20 0.33
TRPM8 Q7Z2W7 2/20 0.33
SCD5 Q86SK9 1/20 0.33
PTGER2 P43116 1/20 0.32
NR1D1 P20393 1/20 0.32
NR1H3 Q13133 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098896 0.84 MEN1 (0.45) CXCR3ALDH1A1SMN1; SMN2TRPM8
SCHEMBL1099165 0.83 KMT2A (0.44) OXTRALDH1A1TRPM8NR1H3
SCHEMBL1097657 0.82 PTGER2 (0.43) TRPM8PTGER2NR1D1NR1H3
SCHEMBL1098834 0.81 HTT (0.36) GRM4ALDH1A1TRPM8KDM4E
SCHEMBL1099073 0.80 CYP3A4 (0.36) GRM4TRPM8
SCHEMBL1101423 0.80 MEN1 (0.47) ALDH1A1KCNA5TRPM8
SCHEMBL1099306 0.78 TRPM8 (0.45) NFE2L2TRPM8
SCHEMBL1100165 0.78 ALDH1A1 (0.44) GRM4CXCR3ALDH1A1SMN1; SMN2TRPM8
SCHEMBL1097838 0.78 ALDH1A1 (0.44) CXCR3ALDH1A1SMN1; SMN2TRPM8KDM4E
SCHEMBL1098433 0.78 RIPK1 (0.34) GRM4TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 GRM4 210/4885CXCR3 2180/4885OXTR 1405/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 GRM4 210/4885CXCR3 2180/4885OXTR 1405/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 GRM4 210/4885CXCR3 2180/4885OXTR 1405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.